Financial Perspectives’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Financial Perspectives’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10	Closed	-$251	–	707
2022 Q3	$251	Hold	10	–	–	﹤0.01%	669
2022 Q2	$304	Hold	10	–	–	﹤0.01%	665
2022 Q1	$328	Hold	10	–	–	﹤0.01%	667
2021 Q4	$264	Buy	+10	New	+$774	﹤0.01%	638

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Financial Perspectives's RETA Position: Q4 2022 in Review

Financial Perspectives sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 10 shares — an estimated $251 sold.

Financial Perspectives first reported a position in RETA in Q4 2021 and held it in 4 quarters. The position peaked at $328 in Q1 2022. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Financial Perspectives reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Financial Perspectives sold 10 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $251.
Financial Perspectives first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 4 quarters.
Financial Perspectives's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $328 in Q1 2022.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Financial Perspectives's 13F filing for Q4 2022, filed 10 Jan 2024.